Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

Organon

Status and phase: Completed; Phase 3

Conditions: Androgenetic Alopecia

Treatments: Drug: MK0906, finasteride / Duration of Treatment : 48 Weeks; Drug: Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00396175

2006_556

0906-111

Details and patient eligibility

About

A clinical study to collect additional data in order to characterize the reduction in PSA with finasteride 1 mg, and its reversibility in men with androgenetic alopecia between the ages of 40 to 60 years.

Sex: Male

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

• Men 40 to 60 years of age, and in good general physical and mental health, with androgenetic alopecia

Exclusion Criteria :

• History of previous bladder surgery, acute urinary retention, urethral strictures, repeated urethral catheterizations, repeated urinary tract infections, or active urinary tract infections
• History of treatment with finasteride (PROSCAR or PROPECIA) or hypersensitivity to any component of finasteride.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind